+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the real-world effectiveness of deucravacitinib in adults diagnosed with moderate-to-severe plaque psoriasis. This observational study aims to understand how this treatment works outside of controlled clinical trials, focusing on health outcomes important to patients and doctors. It is sponsored by Bristol-Myers Squibb and conducted in France. Participants in this study have started treatment with deucravacitinib as prescribed by their doctors. The study observes these patients over time without altering their treatment plans. There are no placebo or comparison groups since this is an observational study that follows patients initiating deucravacitinib treatment. During the study, doctors will assess skin condition using the Physicians Global Assessment and measure quality of life with the Dermatology Life Quality Index at baseline and several points up to 24 months. Patients will also report symptoms like itch, skin pain, and fatigue using visual scales. Researchers will track how long patients remain on treatment and reasons for stopping. The study involves regular follow-ups at months 1, 4, 12, 18 optional, and 24 to gather this information.

Age: 18Years +All Genders
48 locations
S

Actively Recruiting

Pemphigus diseases are serious, chronic autoimmune conditions that cause blistering due to the immune system attacking certain skin proteins. The two main types studied here are pemphigus vulgaris and pemphigus foliaceus. Researchers are evaluating a new personalized maintenance therapy involving rituximab infusions guided by antibody levels to see if this approach can better prevent disease relapses compared to the standard treatment. This is a phase 4 randomized study conducted by the University Hospital, Rouen, building on previous rituximab trials that led to regulatory approvals. Participants in the trial will receive initial treatment with rituximab and oral prednisone following French guidelines, with rituximab given at Day 1, Day 14, Month 12, and Month 18. One group will receive this standard regimen, while the experimental group will have their treatment adapted based on anti-desmoglein antibody levels. Additional rituximab infusions may be given at Month 6 or later if antibody levels remain high or increase, with up to two extra infusions per year allowed during the study. During the study, participants will be regularly monitored through blood tests for antibody levels and blood cells every three months for up to 7.5 years. Researchers will assess the number of disease relapses, time to relapse, duration of remission, quality of life, and rituximab exposure. The study will also track the total dose of rituximab and record safety outcomes. This long follow-up aims to understand if personalized maintenance with rituximab can reduce relapses and the need for corticosteroid treatment.

Age: 18Years - 80YearsAll GendersPhase 4
34 locations
S

Actively Recruiting

This research focuses on classifying genetic variants found in families with a history of hereditary cancer, especially breast and ovarian cancers. It aims to improve genetic counseling by studying the co-segregation of specific gene variants, including those in BRCA1, BRCA2, PALB2, and other genes tested in multigene panels. The study uses data from large French national databases to better understand the disease risk linked to these variants and to support clinical decision-making. Participants include index cases carrying variants of interest classified as class 3 variants of uncertain significance, class 4 likely pathogenic, or hypomorphic class 5 with intermediate effects. The study collects saliva samples from family members to test for these variants and applies statistical models to evaluate the likelihood that a variant causes disease. Genetic analyses are performed by partner laboratories, and results contribute to refining variant classification and recommendations. During the study, participants provide saliva samples for genetic testing and consent to share their data anonymously for analysis. Researchers monitor co-segregation of variants with disease in families over up to 15 years. The main outcome is the classification of selected variants based on family data, which may impact genetic counseling and clinical management. Results are shared at the group level without revealing individual test outcomes.

Age: 18Years +All GendersPhase Not Applicable
62 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
I

Actively Recruiting

Researchers are evaluating the use of a shared decision-making tool to help women with acute cystitis understand the benefits and risks of taking antibiotics. The study compares this approach with the standard French delegation protocol that usually recommends systematic antibiotic therapy for acute cystitis without risk of complication. This research aims to reduce unnecessary antibiotic use while ensuring appropriate treatment for those who need it. The study involves two groups of women aged 18 to 65 who visit participating pharmacies with symptoms of uncomplicated acute cystitis. One group follows the standard delegation protocol alone, while the experimental group uses the same protocol supplemented by a shared decision-making tool to decide on antibiotic use. After diagnosis and eligibility confirmation, patients receive care according to their group assignment. Participants are followed up by phone 14 days after inclusion to assess antibiotic use, symptom impact using the Activity Impairment Assessment scale, satisfaction, decision conflict via the OConnor scale, and any medical consultations or emergency room visits. Antibiotic dispensing is tracked through the national assurance system. This follow-up helps measure treatment decisions and patient outcomes related to the use of the decision support tool.

Age: 18Years - 65YearsFEMALEPhase Not Applicable
26 locations
S

Actively Recruiting

Researchers are evaluating the impact of relaxing touch on the use of chemical restraint in patients who are sedated and intubated in intensive care. This randomized prospective study focuses on patients from the time sedation is lifted until they are extubated. The trial aims to understand whether touch relaxation can influence the need for chemical restraint in this critical care setting. Participants are randomly assigned to one of two groups. One group will receive no relaxing touch and acts as the control. The other group will receive relaxing touch therapy twice daily, consisting of 30-minute massages divided equally among the head, feet, and hands. This intervention is delivered during the intensive care stay, specifically between sedation lifting and extubation. During the study, researchers will monitor chemical restraint use over one year, along with occurrences of self-extubations. Patient discomfort, respiratory rate, and heart rate will be assessed at multiple time points within 90 minutes after the intervention. The study involves close follow-up to measure these outcomes and the ratio of chemical restraint use. The total duration includes assessments during the hospital stay and follow-up over the year.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

This research evaluates the diagnostic performance of a new Clinical Decision Support tool using fresh plasma samples in patients suspected of venous thromboembolism VTE, including pulmonary embolism PE and deep vein thrombosis DVT. It compares results from fresh plasma with those from frozen plasma and the current standard diagnostic strategy. The study includes various patient groups, such as those eligible for D-dimer testing, patients with high clinical probability, patients with conditions affecting D-dimer levels, those with recent thrombotic events, active cancer, or COVID-19. The study uses routine coagulation tests and the new Clinical Decision Support algorithm on both fresh and frozen plasma samples. The algorithm applies manual or machine learning methods to calculate exclusion scores based on D-dimer and fibrin formation assays. Participants receive standard care and diagnosis according to usual practice while their plasma samples are assessed for comparison. Participants will undergo plasma sampling for routine coagulation and Clinical Decision Support testing on fresh and frozen samples. Researchers will measure outcomes including reproducibility, threshold settings, sensitivity, specificity, likelihood ratios, exclusion percentages, and negative predictive values of the Clinical Decision Support tool over periods of 37 to 48 months. The study aims to verify if fresh plasma testing can match frozen plasma performance, potentially impacting diagnostic algorithms for VTE.

Age: 18Years +All Genders
4 locations
S

Actively Recruiting

This research aims to confirm and support the safety and clinical performance of eight different iVascular devices used for endovascular interventions in patients with artery disease affecting the renal, iliac, or femoral arteries. The study involves a real-world population of 209 patients who have undergone these procedures as part of standard care. The goal is to evaluate these devices in typical clinical settings to better understand their use and outcomes. Participants will undergo the same endovascular intervention procedure using one or more of the investigational devices from iVascular. These devices include the Oceanus 18 and Oceanus 35 Balloon Dilatation Catheters, Luminor 18 and Luminor 35 Drug Coated Balloons, Restorer Peripheral Stent System, iVolution Pro Peripheral Self-Expanding Stent System, iCover Covered Peripheral Stent System, and Sergeant Peripheral Support Catheter. The procedure and device use follow the instructions for use specific to each device. During the study, researchers will monitor patients from the time of procedure up to two years afterward. They will assess freedom from serious adverse events and device-related events as primary safety measures, along with the technical success of the procedure. Physicians will also provide ratings of the devices during the procedure. Follow-up includes an exploratory endpoint assessment up to two years post-procedure to understand longer-term outcomes and device performance.

Age: 18Years +All Genders
6 locations
O

Actively Recruiting

Researchers are conducting a non-interventional observational study to follow patients with Chronic Obstructive Pulmonary Disease COPD who are treated with dupilumab as part of their usual medical care. The study aims to describe patient characteristics, assess safety, and evaluate patient-reported outcomes over a long-term period. This study will include about 350 to 500 participants across up to 50 sites in France. Participants will be observed for approximately 36 months without altering their routine treatment. The study collects data retrospectively and prospectively on patients newly started on dupilumab for COPD, as determined by their treating physician according to approved guidelines. There is no randomization or placebo group since this is an observational study. During the study, participants medical records and clinical data will be reviewed regularly to analyze demographics, disease history, treatment history, lung function, symptom assessments, and exacerbation rates. Researchers will track changes in lung function tests, COPD assessment scores, hospitalizations, adverse events, and reasons for treatment discontinuation over three years. Participants will not have to undergo additional treatments, but their health will be monitored as part of this long-term observational study.

Age: 18Years +All Genders
28 locations
G

Actively Recruiting

This research aims to collect detailed, long-term information about patients with Lysosomal Acid Lipase LAL Deficiency, a rare genetic disorder caused by a deficiency of the enzyme responsible for breaking down certain fats in the body. The condition can present as a severe and rapidly progressing disease in infants or a more chronic illness in children and adults, affecting the liver, spleen, and lipid levels, and leading to serious health complications including liver damage and cardiovascular risks. The study focuses on understanding the diseases natural history and variability to improve patient care worldwide. This is an observational, multi-center, international disease registry where patients diagnosed with LAL Deficiency, regardless of their treatment status, are followed over time. The registry collects real-world data to evaluate the long-term outcomes and effectiveness of treatments including sebelipase alfa. Participation is voluntary for both patients and physicians, and the study includes patients living with the disease as well as those deceased. Participants contribute data through their regular medical care and follow-up visits, with researchers gathering information about disease progression, treatment responses, and clinical outcomes. The primary goal is to enhance knowledge about LAL Deficiency by monitoring varied patient experiences and health changes over time. The study is ongoing and aims to support clinical practice and regulatory commitments related to sebelipase alfa therapy. The total duration of participation varies based on ongoing data collection.

All AgesAll Genders
104 locations

1-10 of 20

1